Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_assertion type Assertion NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_head.
- NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_assertion description "[Resistance to tyrosine kinase inhibitors in patients with chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-positive ALL) is frequently caused by mutations in the BCR-ABL kinase domain.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_provenance.
- NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_assertion evidence source_evidence_literature NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_provenance.
- NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_assertion SIO_000772 23190221 NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_provenance.
- NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_assertion wasDerivedFrom befree-20150227 NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_provenance.
- NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_assertion wasGeneratedBy ECO_0000203 NP219645.RASce_pUEQK6OHOXT2QGfhbNoxcdNZ3sZJ5N-VAswho0E130_provenance.